News

Penta at IAS and the International Workshop on HIV Pediatrics 2021

Tags: , , | July 15th, 2021

This year, at the International Workshop on HIV Pediatrics and IAS our ODYSSEY and SMILE studies and EPIICAL will be presenting abstracts in various sessions.

 

The International Workshop on HIV Pediatrics 2021 will be taking place from the 16th to the 17th of July 2021. It is considered to be the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers. Find out more about the workshop here.

Penta presentations: HIV Pediatics Workshop

Pediatric treatment Session

ODYSSEY Dolutegravir-Based ART is superior to Standard of Care in young children living with HIV. Pauline Amuge
SMILE

Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial. Alexandra Compagnucci


Complications of Pediatric or Maternal ART – Abstract session 2

ODYSSEY Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial. Ciccy Kityo
ODYSSEY

Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial. Hilda Angela Mujuru


Poster Presentations

EPIICAL Early-Treated Infants living with HIV typically recover their Cd4+ T-Cell counts but not their Cd4+ T-cell percentages. Juliane Schröter, Anet J.N. Anelone & Rob J. de Boer (on behalf of the EPIICAL consortium)
ODYSSEY Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial.
ODYSSEY No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial
ODYSSEY Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial
ODYSSEY Exposure to two dolutegravir formulations in children in the ODYSSEY trial

 

IAS will be held from the 18th till the 21st of July 2021 as a hybrid congress, making it accessible to more researchers across the globe. IAS is considered the world’s most influential conference on HIV Science. Find out more about IAS here

 

Penta presentations: IAS 

On demand oral abstract session

ODYSSEY

Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial. Anna Turkova


Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations

ODYSSEY

On demand e poster: No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial. Tom Jacobs


Clinical trials in paediatric and adolescent populations

ODYSSEY Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial. Linda Barlow-Mosha
ODYSSEY Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial. Anna Turkova
SMILE Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial. Alexandra Compagnucci
ODYSSEY A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial. Abbas Lugemwa
ODYSSEY Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial. Cissy Kityo
NEWSLETTER

We would like to update you on our recent activities